F 50003
Latest Information Update: 12 Jan 2004
At a glance
- Originator Pierre Fabre
- Class
- Mechanism of Action Undefined mechanism
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
Highest Development Phases
- No development reported Influenza virus infections
Most Recent Events
- 12 Jan 2004 No development reported - Preclinical for Influenza virus infections in France (Injection)
- 16 May 2001 Pierre Fabre has merged with bioMérieux Alliance
- 27 Apr 1999 New profile